Last reviewed · How we verify
NCT05657938
Evaluation of Home Based Assessments on Participants With DMD
trial testing Wearable Device in Duchenne Muscular Dystrophy in 17 participants. Completed in 4 April 2023.
4 April 2023
Quick facts
| Lead sponsor | Solid Biosciences Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 17 |
| Start date | 13 October 2022 |
| Primary completion | 4 April 2023 |
| Estimated completion | 4 April 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Wearable Device
- Duchenne Video Assessment (DVA)
Conditions studied
- Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →
Sponsor
Solid Biosciences Inc. — full company profile →
Who can join
Adults 4 to 12, male only, with Duchenne Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the feasibility, wearability and participant satisfaction of novel outcome assessment tools in DMD patients which are performed in the home environment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Real-World Postural Transitions as Biomarkers of Functional Impairment in Duchenne Muscular Dystrophy.
Gramling CJ, Kairamkonda DD, Marshall JL, Morris C, et al · · 2025 · PMID 40416999 · DOI 10.1159/000545617
Verify or expand the search:
- PubMed search for NCT05657938
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Wearable Device
Trials testing the same drug.
- NCT06092138 — Edge Computing Platform for Spine Health Risk Management Based on IoT Technology · NA · completed
- NCT03416634 — Exercise is Medicine at Emory Seavey Internal Medicine Clinic · NA · completed
Other recruiting trials for Duchenne Muscular Dystrophy
Currently open trials in the same condition.
- NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
- NCT06817382 — A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Ma · Phase 1 · recruiting
- NCT06402942 — Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy · NA · recruiting
- NCT06450639 — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) · Phase 2 · active not recruiting
- NCT06692426 — Trial of Cell Based Therapy for DMD · Phase 1 · recruiting
Other Solid Biosciences Inc. trials
Trials by the same sponsor.
- NCT07180355 — A Study of SGT-212 Gene Therapy in Friedreich's Ataxia · Phase 1 · recruiting
- NCT06138639 — A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) · Phase 1, PHASE2 · recruiting
- NCT03368742 — Microdystrophin Gene Transfer Study in Adolescents and Children With DMD · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05657938 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Solid Biosciences Inc.
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05657938.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing